Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact.

Autor: Armstrong E; Department of Medicine, University of Toronto, Toronto, Canada. ericm.armstrong@mail.utoronto.ca., Hemmerling A; Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, USA., Miller S; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, USA., Huibner S; Department of Medicine, University of Toronto, Toronto, Canada., Kulikova M; Toronto General Hospital Research Institute, University Health Network, Toronto, Canada., Crawford E; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, USA., Castañeda GR; Chan Zuckerberg Biohub, San Francisco, USA., Coburn B; Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.; Department of Medicine, University Health Network, Toronto, Canada., Cohen CR; Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, USA., Kaul R; Department of Medicine, University of Toronto, Toronto, Canada.; Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.; Department of Medicine, University Health Network, Toronto, Canada.
Jazyk: angličtina
Zdroj: Microbiome [Microbiome] 2024 Jun 21; Vol. 12 (1), pp. 110. Date of Electronic Publication: 2024 Jun 21.
DOI: 10.1186/s40168-024-01828-7
Abstrakt: Background: Bacterial vaginosis (BV) increases HIV acquisition risk, potentially by eliciting genital inflammation. After BV treatment, the vaginal administration of LACTIN-V, a live biotherapeutic containing the Lactobacillus crispatus strain CTV-05, reduced BV recurrence and vaginal inflammation; however, 3 months after product cessation, CTV-05 colonization was only sustained in 48% of participants.
Results: This nested sub-study in 32 participants receiving LACTIN-V finds that 72% (23/32) demonstrate clinically relevant colonization (CTV-05 absolute abundance > 10 6  CFU/mL) during at least one visit while 28% (9/32) of women demonstrate colonization resistance, even during product administration. Immediately prior to LACTIN-V administration, the colonization-resistant group exhibited elevated vaginal microbiota diversity. During LACTIN-V administration, colonization resistance was associated with elevated vaginal markers of epithelial disruption and reduced chemokines, possibly due to elevated absolute abundance of BV-associated species and reduced L. crispatus. Colonization permissive women were stratified into sustained and transient colonization groups (31% and 41% of participants, respectively) based on CTV-05 colonization after cessation of product administration. These groups also exhibited distinct genital immune profiles during LACTIN-V administration.
Conclusions: The genital immune impact of LACTIN-V may be contingent on the CTV-05 colonization phenotype, which is in turn partially dependent on the success of BV clearance prior to LACTIN-V administration.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: